Brill et al. identified the Kir4.1 antibodies in serums from 26.3% (21 of 80) of patients with MS, 22.2% (10 of 45) of patients with neuromyelitis optica (NMO), and 6.7% (2 of 32) of HCs using the same peptide Kir4.183–120 ELISA [46]. Here, KCNJ10 is linked to myeloid sarcoma.